共查询到18条相似文献,搜索用时 218 毫秒
1.
目的:比较玻璃体腔注射康柏西普和雷珠单抗治疗1型早产儿视网膜病变(ROP)的有效性和安全性。方法:回顾性收集2018-08/2020-01于西京医院眼科确诊为1型ROP,并进行玻璃体腔注射康柏西普(IVC组,46例91眼)或雷珠单抗(IVR组,55例109眼)治疗的患儿临床资料,比较治疗后两组患儿ROP病变消退、复发及再治疗情况,不良预后及眼部和全身并发症情况。结果:纳入患儿101例200眼中急进型后极部ROP(AP-ROP)20眼,阈值期ROP 86眼,阈值前期1型ROP 94眼。两组患儿基线资料及治疗前ROP严重程度均无差异(P>0.05)。IVC组和IVR组一次治愈率无差异(93.4%vs 87.2%,P>0.05)。一次治疗后IVC组复发6眼(6.6%),平均复发时间为11.7±4.13wk,其中2眼再次行IVC治疗,4眼行视网膜激光光凝治疗,治疗后病变均消退;IVR组复发11眼(10.1%),平均复发时间9.82±4.02wk,其中4眼再次行IVR治疗,7眼行视网膜激光光凝治疗,治疗后病变均退行;两组复发率及复发时间均无显著差异(P>0.05)。IVC组一次治疗后未见病变进展;IVR组一次治疗后3眼病情进展,其中2眼视网膜增殖加重伴出血,行视网膜激光光凝治疗,1眼进展为牵拉性视网膜脱离,行玻璃体切除术治疗。两组患儿治疗后均未出现与药物或玻璃体腔注射相关的眼部及全身并发症,IVR组3眼出现颞侧视网膜皱褶,视网膜血管牵拉致血管弓夹角变小等不良预后。结论:IVC和IVR均为1型ROP治疗的有效手段,两者一次治愈率、复发率无显著差异,但IVR治疗的部分病情严重患儿有出现病变进展或不良预后的可能,需长期严密观察随访。 相似文献
2.
目的观察雷珠单抗玻璃体内注射治疗1型阈值前病变早产儿视网膜病变(retinopathy of prematurity,ROP)的疗效。方法回顾性分析2016年4月至2017年8月在我院眼科检查确诊并接受雷珠单抗玻璃体内注射治疗的1型阈值前病变ROP患儿,所有患儿在确诊后72 h内行雷珠单抗0.25 mg/0.025 mL玻璃体内注射,首次注药后2 d、1周、2周以及接下来根据患儿病情决定随访频率并观察治疗效果。结果 12例(20眼)ROP患儿接受雷珠单抗玻璃体内注射治疗,所有眼玻璃体内注射雷珠单抗均有疗效,3例(5眼)出现ROP复发,平均复发时间在治疗后8.8周。1例患儿在双眼注射雷珠单抗后出现单眼复发,所有复发眼接受二次复发时间雷珠单抗玻璃体内注射。末次随访时除1例(2眼)外,其他患眼均达到Ⅲ区血管化。除少量局限的视网膜出血外,未发现与注药治疗相关的局部及全身并发症。结论雷珠单抗玻璃体内注射治疗1型阈值前病变ROP效果明确,可使视网膜血管继续生长,但存在一定的复发率。 相似文献
3.
目的:探讨手术前玻璃体腔注射雷珠单抗对增生型糖尿病视网膜病变(prolifertive dibetic retinopthy,PDR)患者25G微创玻璃体视网膜手术(vitreoretinal surgery,VRS)围手术期指标的影响.方法:采用回顾性研究.选取2013-02/2015-12我院接受VRS治疗的PDR患者74例82眼,根据术前玻璃体腔是否注射雷珠单抗分为VRS+术前玻璃体腔注射雷珠单抗组和仅行VRS组.记录VRS手术时间、填充物情况、医源性视网膜裂孔等情况.结果:VRS+术前玻璃体腔注射雷珠单抗组手术时间和电凝次数均显著低于VRS组,两组手术时间和电凝次数比较差异均有统计学意义(P<0.05);VRS+术前玻璃体腔注射雷珠单抗组医源性视网膜裂孔发生和使用硅油为填充物的例数均低于VRS组,两组比较差异均有统计学意义(P<0.05);而使用C3F8和灌注液作为填充物的例数比较差异均无统计学意义(P>0.05);VRS+术前玻璃体腔注射雷珠单抗组术后3mo内有4眼出现玻璃体再积血,VRS组术后3mo内有13眼出现玻璃体再积血,两组患者术后3mo内出现玻璃体再积血发生率比较差异有统计学意义(x2=4.966,P<0.05).结论:PDR患者25G微创VRS术前玻璃体腔注射雷珠单抗治疗能够减少术中眼部出血、视网膜损伤,缩短手术时间,提高手术成功率并降低术后眼部再出血、再粘连等并发症的发生率. 相似文献
4.
目的观察减量阿柏西普治疗早产儿视网膜病变(ROP)的疗效。方法采用非随机对照研究设计,纳入2018年12月至2020年5月于郑州大学第一附属医院就诊的ROP患儿38例76眼,根据监护人意愿将患儿分为雷珠单抗组21例42眼和减量阿柏西普组17例34眼。分别单次玻璃体腔注射雷珠单抗0.025 ml(0.25 mg)或阿柏西普0.0125 ml(0.5 mg)。使用Retcam眼底照相观察注射后1、2、4周及2、3、6个月患者治疗应答情况,并计算2个组单次治疗有效率;使用Icare PRO磁性回弹式眼压计测量药物注射后1、10、30 min眼压;观察6个月随访期内眼部及全身并发症情况。结果单次雷珠单抗和减量阿柏西普玻璃体腔注射后6个月随访期内有效率分别为90.5%(38/42)和88.2%(30/34),2个组比较差异无统计学意义(χ^2=0.10,P=0.75),均未见眼部及全身并发症。术后1 min和10 min雷珠单抗组术眼眼压高于减量阿柏西普组,差异均有统计学意义(均P<0.01),2个组均在术后30 min恢复至基线水平。雷珠单抗组4眼单次注射治疗无效,其中2眼再次注射后有效,1眼行视网膜激光光凝术治疗后有效;1眼因急进型后极部ROP于治疗后1周进展为5期ROP,接受玻璃体切割术后,后极部视网膜复位良好。减量阿柏西普组治疗无效4眼,其中3眼再次注射阿柏西普后有效,1眼行视网膜激光光凝术治疗后有效。随访期内2个组均未见眼部及全身并发症。结论减量阿柏西普治疗ROP安全、有效,且对眼压影响较小。 相似文献
5.
目的 评估行玻璃体腔药物注射Avastin (bevacizumab,rhuMAb-VEGF)治疗的早产儿视网膜病变(retinopathy of Premature,ROP)病例的临床疗效.方法 对2010年7月至2013年9月在广州市妇女儿童医疗中心眼科就诊的22例行玻璃体腔药物注射Avastin治疗的ROP患儿44只眼的临床治疗经过与疗效.所有患儿经筛查确诊后,在24 h内行玻璃体腔注射Avastin 0.03 ml/次,术后3~15 d行第一次复诊,随访8~21周,平均随访时间15周.结果 AP-ROP完全退化6例12只眼,病情控制2例4只眼.全身情况较差的典型ROP患儿完全退化4例8只眼,病情控制2例4只眼.阈值期ROP患儿完全退化4例8只眼,病情控制4例8只眼.结论 对于AP-ROP患儿、典型ROP患儿,单独给予玻璃体腔注射Avastin,可多次给药,每次治疗期限不超过药物半衰期,能控制病情,基本不需要给予激光治疗. 相似文献
6.
目的::探讨玻璃体腔内注射雷珠单抗治疗视网膜中央静脉阻塞并发黄斑水肿的临床疗效。方法:选取2015-03/09我院收治的视网膜中央静脉阻塞并发黄斑水肿患者30例30眼行雷珠单抗玻璃体腔内注射,1次/mo,治疗1~3mo,治疗结束后随诊3mo,比较患者注射后最佳矫正视力、眼压、黄斑中心凹视网膜厚度、黄斑水肿消退率及眼底荧光血管造影检查结果。结果:随着雷珠单抗注射次数的增加,患者的最佳矫正视力逐渐提高(P<0.05),黄斑中心凹视网膜厚度明显下降(P<0.05),眼压与治疗前比较并无明显变化(P>0.05)。第1、2、3次注射后患者黄斑水肿消退率分别为47%、68%、94%。结论:玻璃体腔内注射雷珠单抗能够有效缓解视网膜中央静脉阻塞继发的黄斑水肿,明显改善患者的视力。 相似文献
7.
目的:观察视网膜光凝术联合玻璃体腔注射低剂量雷珠单抗治疗急进型后极部早产儿视网膜病变(ROP)的疗效。 方法:选取2016-03/2018-05在我院新生儿中心住院筛查确诊为双眼急进型后极部ROP的患儿18例36眼,随机分为注药组和联合组,各9例18眼。注药组行玻璃体腔注射雷珠单抗0.4mg,联合组行后极部Ⅰ区及其颞侧2个视乳头直径以外无血管区域激光光凝联合玻璃体腔注射雷珠单抗0.25mg。术后随访12mo以上,观察两组患儿视网膜无血管区血管发育情况,血管嵴、附加病变、虹膜红变消退时间及不良反应发生情况。 结果:术后平均随访18.7±6.3mo,两组患儿视网膜病变和虹膜红变均不同程度消退,视网膜血管继续向周边发育至锯齿缘或病变瘢痕化; 注药组患儿血管嵴、附加病变、虹膜红变消退时间(2.01±0.32、1.92±0.51、1.59±0.07wk)均大于联合组(1.75±0.29、1.75±0.29、1.34±0.18wk)(均P<0.05); 注药组新增视网膜前出血3眼,出血均自行吸收,联合组未出现局部出血及纤维增生。两组患儿术中和术后均未出现严重眼部和全身不良反应。 结论:激光光凝术联合玻璃体腔注射低剂量雷珠单抗治疗急进型后极部ROP安全、有效。 相似文献
8.
目的 观察激光光凝联合玻璃体内注射雷珠单抗治疗早产儿视网膜病变(retinopathy of prematurity,ROP)的安全性及有效性。方法 对32例(64眼)ROP患儿行玻璃体内注射雷珠单抗治疗,观察附加病变、嵴、嵴上新生血管的消退情况以及周边视网膜,其中12例(24眼)附加病变、嵴及嵴上新生血管不完全消退者进行激光光凝治疗。结果 32例64眼ROP患儿中,经玻璃体内注射雷珠单抗治疗病变完全消退者20例40眼,占62.5%;12例24眼病变复发,经联合激光光凝治疗病情稳定,占37.5%。病变复发的24眼中,包括急进型后极部ROP 14眼,阈值期ROP 6眼,阈值前期ROP 4眼。所有患儿视网膜病变不同程度消退。给予玻璃体内注射雷珠单抗治疗后新生血管及出血吸收,血管继续发育至锯齿缘或病变瘢痕化。12例(24眼)病变复发者联合视网膜光凝治疗后病变完全消退。32例ROP患儿眼部及全身未见不良反应。结论 玻璃体内注射雷珠单抗治疗ROP效果好,不但可以使嵴、嵴上新生血管及附加病变完全消退,而且还可使视网膜血管继续生长,对于病变不能完全消退的患儿联合视网膜激光光凝治疗后也可获得较好疗效。 相似文献
9.
目的:探讨象限分类法在1型阈值前期、阈值期早产儿视网膜病变中的应用。 方法:收集2017-04/2018-01来南昌大学附属眼科医院治疗的1型阈值前期、阈值期早产儿视网膜病变患儿32例进行回顾性病例分析。以象限法将这些早产儿视网膜病变病例中的主要病变位置及范围分为三类:仅分布在一个象限(鼻上、鼻下、颞上、颞下)记录为“1个象限”; 分布在两个象限者(颞上+颞下、鼻上+鼻下、鼻上+颞上、鼻下+颞下、鼻上+颞下、鼻下+颞上)记录为“2个象限”,分布超过两个象限者记录为“>2个象限”。通过象限法来观察这些病例的临床特点以及玻璃体腔注射雷珠单抗治疗后的治愈及复发情况。 结果:纳入研究的32例62眼早产儿视网膜病变患儿中,仅分布在1个象限的有2眼(3%),单次玻璃体腔注药治愈构成比100%; 分布在2个象限的共25眼(40%),单次玻璃体腔注药治愈构成比100%; 分布>2个象限的共35眼(56%),单次玻璃体腔注药治愈构成比74%,复发构成比26%。 结论:1型阈值前期、阈值期早产儿视网膜病变的主要病变部位大多数分布在颞侧上下象限,而且分布的象限数越多,病情越严重,玻璃体腔注射雷珠单抗治疗的复发可能性越高。 相似文献
10.
目的:观察玻璃体腔注射康柏西普与雷珠单抗联合黄斑区格栅样激光光凝(macular laser grid photocoagulation,MLG)治疗视网膜分支静脉阻塞(branch retinal vein occlusion,BRVO)继发黄斑水肿(macular edema,ME)的疗效.方法:按照计算机产生随机数将BRVO继发ME患者120例120眼分为3组,各40例40眼,A组:单纯行MLG;B组:玻璃体腔注射雷珠单抗(0.05mL/0.5mg)1wk后给予MLG治疗;C组:玻璃体腔注射康柏西普(0.05 mL/0.5mg)1wk后给予MLG治疗.三组治疗后1mo根据复查FFA、OCT结果对效果不佳患者可重复注射药物.随访6mo,对比B组和C组重复注射率.观察各组治疗前及治疗后1wk,1、3、6mo最佳矫正视力(best corrected visual acuity,BCVA)、黄斑中心凹视网膜厚度(central macular thickness,CMT)结果,统计各组并发症.结果:B组患者连续注射雷珠单抗2次者4眼,连续注射3次者7眼,重复注射率27.5%,C组均注射1次,B组重复注射率比C组高,差异有统计学意义(P<0.05);三组患者治疗后BCVA较治疗前均得到提高,CMT均较治疗前变薄,但B组和C组治疗后BCVA均高于A组,且CMT低于A组.另外,治疗后C组BCVA高于B组,CMT低于B组,但B组和C组BCVA和CMT比较差异无统计学意义(P>0.05);直至随访结束,三组患者均无明显不良反应,B组与C组患者均未复发,A组复发率25%,差异有统计学意义(P<0.05).结论:玻璃体腔注射康柏西普与雷珠单抗联合激光光凝治疗BRVO继发ME疗效均佳,但康柏西普联合激光治疗注射次数相对较少. 相似文献
11.
目的:评价玻璃体注射 bevacizumab 治疗26例Ⅰ区早产儿视网膜病变(retinopathy of prematurity,ROP)的治疗效果。方法:通过回顾性研究,对2013-09/2014-10确诊为Ⅰ区阈值期 ROP 并行玻璃体注射 bevacizumab 治疗的26例患儿分三组(阈值前期Ⅰ型 ROP、阈值期 ROP、急进型后极部早产儿视网膜病变-APROP),进行术后效果分析比较。结果:治疗Ⅰ区高危性阈值期 ROP 患儿26例52眼。其中阈值前期Ⅰ型 ROP 3例6眼,阈值期 ROP 15例30眼, APROP 8例16眼。治疗阈值期Ⅰ型 ROP、阈值期 ROP 和APROP 的一次手术治愈率分别为100%(6/6)、60%(18/30)和75%(12/16),三组之间手术治愈率无统计学差异(P>0.05)。 结论:玻璃体腔内注射 bevacizumab 治疗Ⅰ区 ROP 的临床疗效明确,比传统光凝术治疗具有一定优越性,可作为 I区 ROP 的一线治疗方法。 相似文献
12.
PurposeTo report on 2 cases of aggressive posterior retinopathy of prematurity (ROP) treated with intravitreal ranibizumab (Lucentis ®) and laser photocoagulation. MethodsTwo premature females, born at 25 and 26 weeks’ gestation with a birth weight of 530 and 550 g, respectively, with aggressive posterior ROP received combined treatment with laser photocoagulation and intravitreal ranibizumab (0.3 mg [30 µl]) to each eye. Structural outcomes were evaluated by indirect ophthalmoscopy and documented by retinography. ResultsAn intravitreal injection was made at 34 weeks of postmenstrual age in the first case, followed by laser photocoagulation 1 week later. There was a partial regression of ROP with treatment. Five weeks later, neovascularization regrowth with bleeding in both eyes (intraretinal and subhyaloid) occurred and retreatment with combined therapy was performed. In the second case, single therapy with laser photocoagulation was made at 34 weeks of postmenstrual age. In spite of the confluent photocoagulation in the avascular area, progression to 4A ROP stage occurred 1 week later. Both eyes were retreated 1 week later with intravitreal ranibizumab and laser photocoagulation. Treatment resulted in ROP regression in both cases. There were no signs of systemic or ocular adverse side effects. ConclusionThe cases presented show that combination therapy of indirect laser photocoagulation and intravitreal ranibizumab can be effective in the management of aggressive posterior ROP. Further investigation on anti-VEGF safety in premature infants is necessary. Additional studies are needed to define the role of anti-VEGF in ROP treatment.Key Words: Retinopathy of prematurity, Laser photocoagulation, Ranibizumab, Anti-VEGF therapy 相似文献
13.
目的 观察抗血管内皮生长因子(vascular endothelial growth factor,VEGF)治疗不同区域早产儿视网膜病变的临床效果.方法 回顾性分析2013年4月至2014年4月在郑州儿童医院行玻璃体内注射抗VEGF药物的早产儿视网膜病变患儿24例(46眼),分为Ⅰ区病变组15例(28眼),Ⅱ区病变组9例(18眼).所有患者均在全身麻醉下行玻璃体内注射抗VEGF药物雷珠单抗,对患儿术后眼底进展情况进行观察,分析两组首次注射治愈和进展情况以及并发症发生情况.结果 两组间的出生孕周、出生体质量相比,差异均无统计学意义(均为P >0.05);手术矫正孕周相比,差异有统计学意义(P=0.001).24例(46眼)中,首次注射治愈21眼,病情继续发展25眼,治愈率为45.65%,治疗到治愈的时间间隔为2~12个月.Ⅰ区病变组首次注射治愈9眼,治愈率为32.14%,进展率为67.86%;Ⅱ区病变18眼中12眼首次注射治愈,6眼病情继续进展,治愈率为66.67%,进展率为33.34%.两组首次注射治愈率相比,差异有统计学意义(x2=5.263,P=0.022),Ⅰ区病变的首次注射治愈率明显低于Ⅱ区病变.两组进展率相比,差异有统计学意义(x2=-2.269,P=0.023),Ⅰ区病变的进展率明显高于Ⅱ区病变.随访中未发现与玻璃体内注射有关的白内障、眼内炎、视网膜裂孔等出现,仅有2例出现角膜水肿,4例出现结膜下出血,均未做特殊处理自愈.结论 玻璃体内注射抗VEGF药物对于Ⅰ区、Ⅱ区病变均有效,Ⅰ区病变手术成功率低,再次手术的几率大,但可为再次手术创造时间和条件. 相似文献
14.
AIM: To evaluate the effect of intravitreal ranibizumab injection for retinopathy of prematurity (ROP) in Zone II Stage 3+.
METHODS: Data was collected for ROP patients with Zone II Stage 3+ who received intravitreal ranibizumab injections between October 2014 and Janu-ary 2017 at the Department of Ophthalmology in our hospital. No prior laser or other intravitreal treatment was done. Prior to the intervention and at each follow-up visit, fundus examination was performed. Gestational age at birth, sex, birth weight, ROP zone, ROP stage, post menstrual age (PMA) at treatment, and follow-up pe-riod were recorded. The final clinical status of the retina was evaluated for each patient. The primary outcome mea-sures included ROP recurrences requiring re-treatment, complete or incomplete peripheral vascularization.
RESULTS: Eighty-six eyes of 46 premature infants with Zone II Stage 3+ ROP were enrolled in the study. The mean gestational age at birth was 28.18±1.67 (range: 25 to 33)wk and the mean birth weight was 1070.57±226.85 (range: 720.00 to 1650.00) g. The mean PMA at treatment was 38.32±2.99 (range: 32.29 to 46.00)wk. Seventy-one eyes (82.56%) were treated success-fully with intravitreal ranibizumab as monotherapy. Fifteen eyes (17.44%) developed recurrent disease. The mean interval between the treatment and retreatment was 5.96±3.22 (range: 1.86 to 11.71)wk. All eyes vascularized into zone III at the end of the study and among them 62 eyes (72.09%) achieved complete vascu-larization.
CONCLUSION: Intravitreal ranibizumab injection is an effective treatment in Zone II Stage 3+ ROP patients. More patients with longer follow-up duration are necessary to confirm the safety and efficacy of this treatment. 相似文献
15.
AIM:To investigate the clinical manifestations,diagnostic approaches,treatments,and outcomes of intraocular lymphoma.METHODS:In this retrospective study,16 patients(28 eyes)with intraocular lymphoma were recruited in the Department of Ophthalmology,Peking Union Medical College Hospital,from 2004 to 2019.All patients underwent comprehensive ophthalmic examinations.Vitreous specimens of 13 patients were sent for cytopathology examination and other adjunctive diagnostic procedures.Three patients were diagnosed with intraocular lymphoma according to analysis of the histopathological results of systemic lymphoma by one clinician.Twenty-three eyes were treated with intravitreal administration of methotrexate,4 eyes could not receive ocular treatment due to life-threatening lymphoma,and 1 eye did not require ocular treatment because the fundus lesions regressed after systematic chemotherapy.RESULTS:In 28 eyes,25 eyes were diagnosed with vitreoretinal lymphoma,and 3 eyes were diagnosed with ciliary body lymphoma,all of which were non-Hodgkin diffuse large B cell lymphomas.The final visual acuity improved in 15 eyes(54%),remained unchanged in 5 eyes(18%),and decreased in 8 eyes(29%).Anterior segment inflammation disappeared or reduced in 8 and 5 eyes,respectively;and 15 eyes had no anterior segment reaction.Twenty eyes had mild vitreous opacity,1 eye had mild vitritis,and 7 eyes had pars plana vitrectomy combinedwith silicone oil tamponade.Fundus lesions disappeared in 9 eyes and were relieved in 5 eyes;4 eyes showed no changes,and the remaining 10 eyes’fundus were normal.CONCLUSION:The clinical manifestations of intraocular lymphoma are diverse,and the misdiagnosis rate is high.Cytopathological analysis of vitreous is one of the gold standards for the diagnosis.Immunohistochemistry,gene rearrangement and flow cytometric immunophenotypic analysis can improve the diagnostic rate.Ocular chemotherapy or radiotherapy regimens may preserve visual acuity,and a multidisciplinary team can provide individualized treatment for the patients. 相似文献
16.
AIM: To assess the effect of intravitreal ranibizumab injection for retinopathy of prematurity (ROP) in Zone II Stage 3+.
METHODS: Data was collected from ROP patients with Zone II Stage 3+ who had intravitreal ranibizumab injections between October 2014 and January 2017 at the department of Ophthalmology in our hospital. No prior laser or other intravitreal therapy was done. Fundus examination was performed prior to the intervention and at each follow-up visit. Gestational age at birth, birth weight, sex, ROP zone, ROP stage, post menstrual age (PMA) at treatment, and follow-up period were recorded. The final clinical status of the retina was noted for each patient. The primary outcome measures included ROP recurrences requiring re-treatment, complete or incomplete peripheral vascularization
RESULTS: Eighty-six eyes of 46 premature infants with Zone II Stage 3+ROP were enrolled in the study. The mean gestational age at birth was 28.18±1.67wk (range: 25 to 33wk) and the mean birth weight was 1070.57±226.85 g (range: 720.00 to 1650.00 g). The mean PMA at treatment was 38.32±2.99wk (range: 32.29 to 46.00wk). Seventy-one eyes (82.56%) were treated successfully with intravitreal ranibizumab as monotherapy. Fifteen eyes (17.44%) developed recurrent disease. The mean interval between the treatment and retreatment was 5.96±3.22wk (range: 1.86 to 11.71wk). All eyes vascularized into zone III at the end of the study and among them 62 eyes (72.1%) achieved complete vascularization.
CONCLUSION: Intravitreal ranibizumab injection is an effective treatment in patients with zone II stage 3+ ROP. More patients with longer follow-up duration are mandatory to confirm the safety and efficacy of this treatment. 相似文献
17.
目的:比较康柏西普和雷珠单抗治疗阈值前期1型早产儿视网膜病变(ROP)的疗效。方法:回顾性病例对照研究。选择2017年1月至2019年6月在解放军总医院第七医学中心儿科医学部住院治疗的阈值前期1型ROP且行抗血管内皮生长因子治疗的患儿107例(208眼),其中行康柏西普治疗(IVC)45例(86眼)作为IVC组,雷珠单抗治疗(IVR)62例(122眼)作为IVR组。IVC组中I区病变16例(32眼),II区病变29例(54眼);IVR组中I区病变23例(46眼),II区病变39例(76眼)。术后定期随诊观察眼内炎症反应、ROP病变消退情况、ROP病变复发再治疗率和复发再治疗间隔时间。组间数据比较采用t检验和卡方检验。结果:2组间性别、出生胎龄、出生体质量、治疗时矫正胎龄、病变分区、急进型ROP构成差异均无统计学意义。IVR组和IVC组的复发再治疗率分别为45%和35%,其中I区为61%、63%,II区为37%、19%,2组间II区病变复发再治疗率差异有统计学意义(χ2=5.214,P=0.024)。IVR组和IVC组II区复发再治疗时间分别为注药后(8.8±2.5)周和(11.2±3.1)周,差异无统计学意义。结论:玻璃体腔注射雷珠单抗和康柏西普治疗ROP均有效,治疗后复发与病变分区有关,且康柏西普治疗II区病变复发再治疗率低于雷珠单抗的治疗。 相似文献
18.
目的:观察早产儿视网膜病变(retinopathy of prematurity,ROP)激光光凝术后嵴前部分无血管化区的临床转归,为ROP的临床治疗提供依据.方法:前瞻性随访观察2014-06/2016-06由我院ROP筛查协作组在门诊以及NICU床旁筛查发现并进行视网膜激光光凝治疗的患儿186例372眼,激光光凝术后嵴前存在部分无血管区的患儿26例32眼,其中男17例18眼,女9例14眼,平均出生胎龄(29.4±0.4)周,平均出生体质量1222.8±70.3g,阈值前1型10例12眼,阈值期12例14眼、急性进展性后极部型4例6眼,分别于激光术后1、3、8、12 wk行Retcam眼底照相复查,观察病变嵴、嵴前无血管区以及附加病变的消退情况.随访中如发现病变嵴或附加病变加重,则给予补充视网膜激光光凝或行玻璃体腔抗VEGF治疗,直至病变嵴和附加病变完全消退,病情稳定.结果:患儿26例均在激光术后1 wk复查时发现病变嵴前无血管区,但附加病变减轻,病变嵴由3期向2期、1期消退,阈值前1型消退最明显;3 wk复查时27眼(84%)病变嵴为1期或不明显、无血管区逐渐缩小,视网膜血管向周边发育;5眼(16%)无血管区缩小不显著,附加病变(+~++),病变嵴3~4期、或伴有出血,其中3眼(9%)为阈值期病变患儿,2眼(6%)为急性进展性后极部型患儿,遂及时给予补充视网膜光凝;8 wk复查,未补充视网膜光凝的27眼嵴前无血管区已血管化,嵴及附加病变消退;补充光凝中3眼(9%)病情得到控制、稳定,其中阈值期2眼、急性进展性后极部型1眼,2眼(6%)嵴上新生血管消退不明显、附加病变依然存在,其中阈值期1眼、急性进展性后极部型1眼,故给予玻璃体腔抗VEGF治疗,12 wk复查时见附加病变、病变嵴消退,视网膜血管向颞侧走形稍僵直.结论:视网膜激光光凝是ROP治疗的有效方法,光凝术后嵴前部分无血管区多可自行发育完善.对于少数激光术后病情活动的阈值期及急性进展性后极部型嵴前部分无血管区需及时补充激光光凝治疗,必要时可联合玻璃体腔抗VEGF治疗. 相似文献
|